How much market share for telaprevir?; Allon gains $10M financing deal; FDA balances regulatory, biomedical sciences;

 @FierceBiotech: Next-gen biotechs pursue 'undruggable' targets. Report | Follow @FierceBiotech

 @JohnCFierce: Had a fine time in Boston talking clinical trials with Sanofi, AstraZeneca, Aveo and Cubist Wednesday. Followed up with finance panel in DC Thursday. | Follow @JohnCFierce

TheStreet's Adam Feuerstein surveyed the news coming from the American Association for the Study of Liver Disease meeting and concluded that the only remaining debate to be had related to the prospects of telaprevir and boceprevir was how much market share each was likely to gain. Feuerstein, a longtime and very enthusiastic fan of telaprevir, estimates that the Vertex drug will come out way ahead. Story

> Canada's Allon Therapeutics has closed a $10 million financing agreement with a wholly owned limited partnership of Nordic Biotech Venture Fund II K/S. Allon release

> Dana-Farber and Novartis have triggered a legal wrangle with Gatekeeper Pharmaceuticals over ownership of an anticancer molecules. Article

> Covance has closed on its ambitious R&D deal with Sanofi-Aventis. Report

And Finally... During the MidAtlantic Bio meeting in Bethesda last week the FDA's Joshua Sharfstein was forced to address some barbed questions from members of the audience upset by the agency's tougher safety standards. He responded that the regulatory sciences have to grow in concert with biomedical research in order to find the right balance between breakthroughs and safety. Item

Suggested Articles

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

GigaGen reported that its antibody treatment against COVID-19 was 100 times more protective than plasma and could be ready for human trials in 2021.

Seres Therapeutics is looking for a speedy approval of its once failed drug after it comes through a phase 3 test.